A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PIANO
- 13 Dec 2015 Accrual till date is 4% according to United Kingdom Clinical Research Network record.
- 09 Dec 2015 Planned End Date changed from 1 May 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov record.
- 20 Mar 2014 New trial record